Couple covered under different family Planning methods

1772. PROF. C. LAKSHMANNA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) what is the ratio between the eligible couples covered under permanent methods and temporary methods of family welfare during the first four years of Seventh Five Year Plan; and

(b) what are the details in respect of different States in the country?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) and (b) A Statement giving the national and State-wise percentages of couples estimated to be covered by permanent methods and temporary methods as on the beginning of the Seventh-Plan i.e. 1.4.1985 and as at the end of the Fourth year of the Seventh Plan i.e. 31st March, 1989, is given in the Annexure. (*See* Appendix CL, Annexure No. 87)

Loan licence to manufacture finished medicines by small scale units

1773. DR. (SHRIMATI) SAROJINI MAHISHI:
SHRI CHITTA BASU:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to refer to answer to Starred Question 363 given in the Rajya Sabha on the 28th March, 1989 and state:

(a) what are the names of small scale units in the country in whose favour loan licence to manufacture finished medicines of organised sector have been granted;

(b) what are the names of formulations being marketed by organised sector after getting them produced on loan licence from small-scale units;

(c) whether it is a fact that most of organisd sector units possess the facilities to manufacture those formulations;

(d) if so, whether drugs authorities give loan licences after verifying this aspect;

(e) if not, the reasons therefor;

(f) whether it is a fact that such an arrangement has been made to take advantage of price control order and overcharge price; and

(g) what steps have been taken to rectify the situation in consumer's interest?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) to (g) Loan licences are granted by the Licensing Authorities appointed by the State Governments in their respective States. There are about 8,000 Loan Licence units and about 19,000 drug manufacturing units in the country. The efforts involved in collecting information in respect of so many units from each State/Union Territories will not be commensurate with the results to be achieved. The question of continuance of loan licence system is under review.

Members of Drugs Technical Advisory Board

1774. DR. (SHRIMATI) SAROJINI MAHISHI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to refer to answer to Unstarred Question 221 given in the Rajya Sabha on the 25th April, 1989 and state:

(a) what are the names of the members of Drugs Technical Advisory Board;

(b) what are the terms of reference of this Board;

(c) when were adverse reactions of non-steriodal anti-inflammatory drugs were considered by the Board;

(d) whether the board considered the aspect of alternative safer drugs available in the market; and

(e) what are the basis on which the Board recommended continuation of consumption of drugs which has been withdrawn from other countries?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) and (b) The Drugs Technical Advisory Board is a statutary Board under the Drugs and Cosmetics Act, 1940. The composition and functions of the Board are given in Section 5 of the Act.

(c) to (e) The Drugs Technical Advisory Board had considered the "Boston-Surveillance Study" report on Analgin and had agreed that adverse reactions to Analgin are comparable to that of other painkillers.

The consideration for continued marketing of a drug reported to be withdrawn in some countries is based on therapeutic benefit-risk ratio.

Shifting the category of Timiolol and Paracetamol

1775. DR. GOVIND DAS RICHHARIA:

DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that the Kelkar Committee had discussed with his Ministry the shifting of Timiolol and Paracetamol from Category-I to Category-II;

(b) if so, the basis on which his Ministry agreed to the said proposals;

(c) whether it is also a fact that Timolol is used for National Health Programme and Paracetamol is not used;

(d) on what basis his Ministry endorsed the proposal of Kelkar Committee when Timolol is used for control of blindness; and

(e) what are the details of comments of his Ministry on Paracetamol for shifting the category when Kelkar Committee recommended for price decontrol in its original Report?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) to (e) The information is being collected and will be laid on the Table of the Sabha.

Actified Tablets and Actilex Cough Syrup

1776. DR. GOVIND DAS RICHHARIA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that Actified Tablets, Actilex Cough Syrup are formulations;

(b) whether it is a fact that these formulations contain PsedoEphedrine and Ephedrine;

(c) whether it is a fact that ORS is also a formulation;

(d) whether Kelkar Committee had recommended for price decontrol of drugs going into the production of Actifed Tablets and Actilex Cough Syrup and price control on these formulations;

(e) whether it is also a fact that Kelkaar Committee had also recommended for tonics and vitamin preparations for price control whereas the bulk drugs going into their production are price decontrolled;

(f) whether the Kelkar Committee has consulted his Ministry before making recommendation for price decontrol of ORS and informed these facts; and

(g) if so, what was the reaction of this Ministry and if not, the reasons for making recommendation without the consultation of his Ministry?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): As per the information received from the Department of Chemicals & Petrochemicals the reply is as under:

(a) Yes, Sir.

(b) Actifed contains Pseudo-Ephedrine and Actilex Cough Syrup contains Ephedrine as one of the active ingredients;

(c) Yes, Sir.

(d) and (e) A final view on the recommendations of the Kelkar Committee in this regard is yet to be taken by the Government.